Infantile Spasms (IS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Infantile spasms, also known as West syndrome, represent a distinct and often devastating form of epilepsy affecting infants. It is characterized by unique seizure episodes called infantile spasms, which manifest as flexor, extensor, or mixed flexor-extensor spasms. These spasms are accompanied by a distinctive electroencephalography (EEG) pattern known as hypsarrhythmia and developmental delays or regressions. The syndrome can be categorized into two types based on etiology: symptomatic and cryptogenic. Symptomatic cases are associated with identifiable underlying causes or significant developmental delays preceding the onset of spasms. In contrast, cryptogenic cases lack such clear underlying causes and typically involve normal development before spasms onset. Causes of infantile spasms may stem from prenatal, perinatal, or postnatal factors, with approximately half of the cases attributed to prenatal factors, including central nervous system malformations, intrauterine insults, neurocutaneous syndromes such as tuberous sclerosis complex (TSC), metabolic disorders, and genetic syndromes like Down syndrome. Treatment options for infantile spasms include two medications, adrenocorticotropic hormone (ACTH) and vigabatrin, both supported by strong evidence of efficacy. Older drugs such as phenobarbital, carbamazepine, or phenytoin are seldom effective in managing this condition.

·       Infantile spasms have an incidence of 1.6 to 4.5 per 10,000 live births, estimated to be about 2000 to 2500 new cases per year.

 

Thelansis’s “Infantile Spasms (IS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Infantile Spasms (IS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Infantile Spasms (IS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Infantile Spasms (IS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Infantile Spasms (IS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Infantile Spasms (IS), Infantile Spasms (IS) market outlook, Infantile Spasms (IS) competitive landscape, Infantile Spasms (IS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)